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ABSTRACT 
Introduction: In the European Union companies only need to demonstrate that the risk-benefit 
balance of the new drug is favourable to obtain the authorization to sell new drugs. Hence a 
comparison with available treatments, a cost-effectiveness analysis and the place in the therapy 
of the new drug are not required. Therefore, it is necessary to carry out these analyses in an 
additional study. In Spain there is no national government agency, which conducts a centralized 
evaluation and makes decisions on funding and are the Pharmacy and Therapeutics committees 
that take mandatory decisions for the entire region.  
Objectives: To identify all drug assessments and health technology assessment reports of the 
enzymatic replacement treatments for the four LSD considered in this study, including 
Mucopolysaccharidosis (MPS), Gaucher, Fabry and Pompe disease at the national, regional and 
hospital level; and to summarize the efficacy in terms of outcome measures, adverse events, 
economic impact and final recommendations and indicate potential improvements.  
Methods: 19 reviews at the regional and hospital level and one therapeutic positioning report at 
national level for MPS were considered for this.  
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Results: In general, the drugs evaluated in LSD have demonstrated to be effective in the most 
frequent clinical forms of disease. However, there are clinical phenotypes that still do not have 
available an effective treatment.  
Conclusions: It is expected that new therapies, such as intrathecal therapies or gene therapy 
could be evaluated in the different types of LSD demonstrating positive effects, especially in the 
previous phenotypes. 
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More than 50 rare metabolic disorders caused by the accumulation of non-degraded substrates 
in lysosomes due to an enzymatic defect are considered lysosomal storage diseases (LSDs) [1]. 
The specific LSDs considered in this review are mucopolysaccharidosis (MPS) [2,3], Gaucher 
disease [4,5], Pompe disease [6,7] and Fabry disease [8,9] which involve the accumulation of 
glycosaminoglycans, glucocerebrosides, glycogen and sphingolipids, respectively. Although most 
of the above mentioned diseases are autosomal recessively inherited, a fraction of them, such as 
Fabry disease and MPS type II, follow an X-linked recessive inheritance. Current treatment of 
LSDs in Spain is mostly centred on enzymatic replacement therapy (ERT).  
In order to authorize the sale of a new drug in the European Economic Area (EEA), 
pharmaceutical companies are not required to provide evidence of the cost-effectiveness or place 
in the treatment of such drug [10]. A positive resolution can be obtained from national institutions 
or from the European Medicines Agency (EMA) through the risk-benefit balance of the therapy 
studied [11,12].  
This being the case, and due to the fact that most of the drugs that are available in Spain are 
funded by the public health service, further studies need to be developed to determine the drug’s 
place in therapy and cost-effectiveness [13].  
Health institutions and Pharmacy and Therapeutics Committees (PTCs) in distinct regions of 
Spain carry out drug evaluations and decision-making at the autonomic level. The results are 
described in Health Technology Assessment (HTA) reports containing specific recommendations, 
which may or may not be followed by hospital and prescribers [14].  
The PTCs specifically evaluate those drugs that are dispensed by the hospital pharmacy service 
or are administered directly to patients. The used drugs are selected by means of 
phamacoeconomic, efficacy, efficiency and safety relevance in comparison to the alternative 
drugs in the market and included in the hospital formulary [15]. 
Additionally, the Spanish Agency of Medicines and Health Products (AEMPS), which is 
associated to the national health ministry implements baseline evaluations regarding 
effectiveness, appropriate use and efficiency of the therapeutics according to legislation and 
carries out budget management and standardization at a national level. This information is 
displayed in Therapeutic Positioning Reports (TPR).   
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This study has two different objectives: 1) to identify all drug assessments and health technology 
assessment (HTA) reports of the current treatment for the four LSD considered in this study, 
including Mucopolysaccharidosis (MPS), Gaucher disease, Fabry disease and Pompe disease at 
the national, regional and hospital level; 2) to summarize the efficacy in terms of outcome 
measures, adverse events, economic impact and final report recommendations and indicate 
potential improvements. 
MATERIAL AND METHODS  
Health technology assessments (HTA) and therapeutic positioning reports (TPR) published since 
2004 were obtained from two different sources, GENESIS [16], a group of evaluation of novelties, 
standardization and research in drug selection, belonging to the Spanish Society of Hospital 
Pharmacy, and AEMPS [17], the Spanish Agency of Medicines and Health Products, respectively.  
A database was constructed in order to analyse and summarize parameters of interest by means 
of an indirect comparison. 
The reports included in this analysis assess the current ERT for treatment of LSD except for one 
report assessing substrate reduction therapy (SRT) for Gaucher type I disease. The final selected 
reports correspond to a total of 20 national therapeutic positioning reports and reviews at the 
regional and hospital level. Specifically, 8 for MPS [18-24], 5 for Gaucher disease [25-28], 4 for 
Fabry disease [29-31] and 2 for Pompe disease [32-33].  
The following parameters were extracted from the reports: agency or hospital where the report 
has been written, drug name, active ingredient, drug presentations, posology and administration 
form, pharmaceutical company that commercializes the drug, price, report publication date, 
evaluated indication, Anatomical Therapeutic Chemical classification (ATC) code, Randomized 
controlled trial  (RTC) methodology, RCTs comparators, primary outcomes measures, secondary 
outcomes measures, efficacy measures results, adverse events, report conclusions and 
recommendations.   
RESULTS 
The reports included in this analysis assess the current treatment of LSD. These correspond to 
20 reviews at the regional and hospital level (Table 1).  
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Review of ERT evaluated in MPS 
1) ELOSULFASE ALFA (VIMIZIM®)  
Elosulfase alfa has been evaluated as an ERT for the long term in patients with confirmed 
diagnostic of MPS type IV A in patients of all ages (Table 2). Considering the efficacy and safety 
results and according to the report conclusions, the treatment of MPS type IV A with elosulfase 
alfa has demonstrated to improve the functional capacity, based on the distance walked in the 
six-minute walking test in comparison with placebo, over a period of 24 weeks. Elosulfase alfa is 
generally well-tolerated among patients although it is important to control reactions related with 
infusion, anaphylactic reactions and development of antibodies against treatment.  
The therapeutic positioning recommendations suggest controlling periodically the possible 
presence of antibodies anti-elosulfase alfa to corroborate if they are affecting the therapeutic 
efficacy. Moreover, treatment with elosulfase alfa should be re-evaluated when: 1) patients do not 
respond according to mobility, respiratory and cardiovascular parameters and quality of life; 2) 
absence of improvement in six-minute walking test after 1-year treatment and/or progression of 
bone affection that leads to the need of wheelchair in those patients in whom treatment has been 
initiated by criteria of impairment mobility; 3) in case of recurrent anaphylactic reaction, not easily 
controllable with usual medication. 
2) LARONIDASE (ALDURAZYME®) 
Laronidase has been evaluated as an ERT for the long term in patients with confirmed diagnostic 
of MPS type I (Table 3). Considering the efficacy and safety results and according to the report 
conclusions, laronidase has demonstrated to improve the respiratory function and physical 
capacity in comparison with placebo, over a period of 26 weeks. Moreover, the efficacy outcomes 
suggest that patients treated with laronidase present a decrease in hepatic volume and urinary 
glycosaminoglycans (GAG) concentration. These efficacy results are estimated to remain stable 
in the long term. 
The therapeutic positioning recommendations suggest treatment with laronidase in patients who 
are: 1) <2 years with normal cognitive function and attenuated phenotype; 2) <2 years with normal 
cognitive function and severe physical impairment, as a previous treatment to HSCT; 3) <2 years 
with cognitive impairment; 4) >2 years without cognitive impairment; 5) >2 years with cognitive 
impairment, as palliative treatment.  
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3) GALSULFASE (NAGLAZYME®) 
Galsulfase has been evaluated as ERT for the long term in patients with confirmed diagnostic of 
MPS type IV (Table 4). Considering the efficacy and safety results and according to the report 
conclusions, galsulfase has demonstrated to improve the resistance of patients based on the 
measures of the distance walked in 12-minute walk test and the number of steps walked up in 3 
minutes in comparison with placebo. Moreover, the efficacy outcomes suggest a significant 
decrease in urinary GAG concentration in patients treated with galsulfase and an improvement of 
pain and joint stiffness based on quality of life parameters. 
The therapeutic positioning recommendations suggest treatment with galsulfase as an alternative 
therapeutic option to conventional treatment of MPS type IV. Given the safety profile of galsulfase, 
it is recommended to control patients during infusion due to the possible onset of anaphylactic 
reactions.  
4) IDURSULFASE (ELAPRASE®) 
Idursulfase has been evaluated as an ERT for the long term in patients with confirmed diagnostic 
of MPS type II (Table 5). Considering the efficacy and safety results and according to the report 
conclusions, idursulfase has demonstrated to improve the resistance and the respiratory capacity 
of patients based on the combined variable analysed in comparison with placebo. Moreover, the 
efficacy outcomes indicate that produces a significant reduction of the GAG concentration in urine, 
as well as contributes to decrease organomegaly.  
The therapeutic positioning recommendations suggest treatment with idursulfase as an 
alternative therapeutic option to conventional treatment of MPS type II.  
Review of ERT evaluated in Gaucher disease 
1) IMIGLUCERASE (CEREZYME®) 
Imiglucerase has been evaluated as an ERT for the long term in patients with confirmed 
diagnostic of type I Gaucher. Imiglucerase is also approved for treatment of type III Gaucher 
disease in patients who present non-neurologic manifestations that are clinically significant (Table 
6). Considering the efficacy and safety results and according to the report conclusions, 
imiglucerase has demonstrated comparable results in terms of efficacy with regard to alglucerase, 
by increasing haemoglobin concentration and platelet count as well as reducing hepatic and 
splenic volumes. These efficacy outcomes are estimated to be stable in the long term. Moreover, 
7 
 
different studies suggest that the clinical response obtained from this treatment is not different 
from that obtained in patients with Gaucher type III. 
The therapeutic positioning recommendations suggest treatment with imiglucerase in paediatric 
population with diagnostic of disease at this age, except in Gaucher type II disease.  
2) VELAGLUCERASE (VPRIV®) 
Velaglucerase has been evaluated as ERT for the long term in patients with confirmed diagnostic 
of type I Gaucher (Table 7). Considering the efficacy and safety results and according to the report 
conclusions, velaglucerase has demonstrated comparable results in terms of efficacy with regard 
to imiglucerase, by increasing haemoglobin concentration and platelet count as well as reducing 
hepatic and splenic volumes. This efficacy outcomes are estimated to be stable in the long term 
even if the dose is reduced a 50%. 
The therapeutic positioning recommendations suggest that given the similar efficacy and safety 
profile of velaglucerase and imiglucerase, the selection of treatment between both drug 
formulations should take into account efficiency criteria. 
3) MIGLUSTAT (ZAVESCA®) 
Miglustat has been evaluated as substrate reduction therapy (SRT) for the long term under 
exceptional conditions in patients with confirmed diagnostic of mild or moderate type I Gaucher 
disease who cannot or do not wish to receive ERT. Miglustat is also approved for paediatric and 
adult patients with Niemann-Pick disease type C (Table 8). Considering the efficacy and safety 
results and according to the report conclusions, miglustat as a maintenance therapy has only 
demonstrated slight changes in organomegaly and hematologic parameters after an evaluation 
of 6 and 12 months. Moreover, it was found that the change of treatment from imiglucerase or 
miglustat + imiglucerase to miglustat as monotherapy resulted in a reduction of the platelet count. 
These results indicate that miglustat may be less effective than treatment with ERT. 
The therapeutic positioning recommendations suggest the use of miglustat as a first choice drug 
in the following cases: 1) naive patients when ERT is contraindicated due to hypersensitivity or 
impossibility of intravenous use; 2) refractory patients or intolerant to ERT; 3) patients well-
controlled in previous treatment with ERT, in whom it is decided to change treatment to miglustat 
as monotherapy due to the improvements in quality of life associated with the oral treatment. 
Review of ERT evaluated in Fabry disease 
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1) AGALSIDASE ALFA (REPLAGAL®) 
Agalsidase has been evaluated alfa as ERT for the long term in patients with confirmed diagnostic 
of Fabry disease (Table 9). Considering the efficacy and safety results and according to the report 
conclusions, agalsidase alfa has demonstrated to reduce the neuropathic pain of maximum 
intensity and also the cardiac deposits of globotriaosylceramide (GL3) in comparison with 
placebo. It has been found also a reduction in left ventricular hypertrophy. Moreover, it has been 
found that agalsidase alfa slightly differs in terms of efficacy from agalsidase beta, considering 
that both have demonstrated to stabilize disease progression, especially with regards to the renal 
function. 
The therapeutic positioning recommendations suggest that given the similar efficacy and safety 
profile of agalsidase alfa and agalsidase beta, the selection of treatment between both drug 
formulations should take into account efficiency criteria. 
 
2) AGALSIDASE BETA (FABRAZYME®) 
Agalsidase beta has been evaluated as ERT for the long term in patients with confirmed 
diagnostic of Fabry disease (Table 10). Considering the efficacy and safety results and according 
to the report conclusions, agalsidase beta has demonstrated to clear the GL3 deposits in capillary 
endothelium of kidneys as well as to reduce these levels in heart and skin in comparison with 
placebo. It has been found also a reduction in left ventricular hypertrophy. Moreover, therapy with 
agalsidase beta slows progression of clinical results of renal, cardiac and cerebrovascular 
complications and death, based on a long term analysis of 30-36 months. 
The therapeutic positioning recommendations suggest that given the similar efficacy and safety 
profile of agalsidase beta and agalsidase alfa, the selection of treatment between both drug 
formulations should take into account efficiency criteria. 
Review of ERT evaluated in Pompe disease 
1) ALGLUCOSIDASE ALFA (MYOZYME®) 
Alglucosidase alfa has been evaluated as ERT for the long term in patients with confirmed 
diagnostic of Pompe disease in adult patients and paediatric population (Table 11). Considering 
the efficacy and safety results and according to the report conclusions, alglucosidase alfa has 
demonstrated to improve with a modest efficacy the functional capacity and to stabilize lung 
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function, based on the variables of six-minute walk test and FVC in comparison with placebo, 
over a period of 78 weeks. Moreover, the efficacy outcomes suggest that this drug is more 
effective in the subgroups of patients with mild or moderate disease. It is worth mentioning that 
the maximum benefit of treatment has been observed during the first 26 weeks and afterwards 
the efficacy is stabilized. 
The therapeutic positioning recommendations suggest that given the efficacy profile of 
alglucosidase alfa, it is estimated that the objective of treatment is prevention of loss tissue and 
muscular function. Therefore, patients in advanced stages of disease who present an irreversible 
affection of fibres and muscular tissues and with a limited repair capability of the impaired tissues 
cannot have benefit from treatment with alglucosidase alfa. Moreover, the safety profile of 
alglucosidase alfa should be evaluated in the long term in order to control the possible 
anaphylactic reactions potentially mortal. 
CONCLUSIONS 
The evaluation reports of ERT have drawn conclusions about its efficacy in treatment for the four 
different LSD considered in this study. However, it is difficult to determine exactly its clinical effect, 
considering that LSD diseases are related to a progressive organ and tissue involvement that 
causes heterogeneous clinical symptoms.  
In patients with MPS, galsulfase, laronidase and idursulfase have demonstrated to improve the 
resistance and respiratory capacity and the last two, to reduce the GAG concentration in urine 
and organomegaly in the short term. Less robust data has been found for elosulfase alfa, which 
benefit is based on the six-minute walk test.  
In patients with Gaucher disease type I, imiglucerase and velaglucerase have shown increasing 
haemoglobin concentration and platelet count as well as reducing hepatic and splenic volumes in 
the short and long term. Miglustat has only demonstrated slight changes in organomegaly and 
hematologic parameters as well as a minor efficacy in comparison with ERT. 
In patients with Fabry disease, agalsidase alfa and beta have demonstrated similar efficacy in 
reduction of the cardiac deposits of GL3 and the left ventricular hypertrophy and stabilization of 
renal function, in the short term. Agalsidase beta also reduces the GL3 levels in kidney and skin 
and can slow the progression to renal, cardiac and cerebrovascular complications and death, 
based on a long-term analysis [22]. 
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In patients with late-onset Pompe disease, alglucosidase alfa has demonstrated to improve the 
functional capacity and to stabilize lung function with modest efficacy. An analysis per subgroups 
indicates there is a higher efficacy in patients with mild or moderate disease. 
Regarding the safety profile of the ERT evaluated in LSD, the main adverse events are reactions 
associated with the administration of the drug and the development of antibodies against 
treatment. In the case of SRT, adverse reactions are more related to gastrointestinal disorders 
and neurologic events.  
Regarding the economic impact of the evaluated drugs, it is estimated these are very expensive 
treatments, highlighting that idursulfase and galsulfase are two of the most expensive drugs. 
Taking into consideration the high cost of these treatments, in addition to a lack of evidence on 
the impact in quality of life and evolving of neurologic disease, it would be necessary to define the 
conditions of indication of these drugs, based on a group of experts. 
Future perspectives  
In order to enhance decision-making and accurate recommendations and indications, future drug 
assessments should be able to present further evidence regarding cost-effectiveness and place 
in treatment. To do so studies should include direct comparisons regarding alternative current 
therapies and more significant or clinically relevant outcome measures.  Real world data studies 
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